Insulet posts 24% increase in revenue

 - 
Friday, March 3, 2017

BILLERICA, Mass. – Insulet Corp. has reported fourth quarter revenue of $103.6 million, representing year-over-year growth of 24%. Net loss was $9.2 million vs. $15.9 million. Fourth-quarter revenue in the U.S. for Omnipod was $61.3 million, a 17% increase, and internationally, $20.8 million, a 35% increase. Revenue from drug delivery was $19.6 million, a 34% increase. Insulet reported full year revenue of $367 million, representing year-over-year growth of 39%. Net loss was $27.2 million vs. $61.6 million. Full-year revenue in the U.S. for Omnipod was $229.8 million, a 21% increase, and internationally, $71.9 million, a 78% increase. Revenue from drug delivery was $65.3 million, a 92% increase. Among Insulet’s highlights in 2016: its divestiture of Neighborhood Diabetes’ medical supplies distribution business to focus on growth opportunities in insulin and drug delivery.